RGRX Live signals | Maximize Profits with Getagraph.com

Live Chart Being Loaded With Signals

Commentary (17 Apr 2024 @ 13:13):

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration...

Stats
Today's Volume	15.00
Average Volume	100.00
Market Cap	209 576
EPS	$-0.00380 ( 2023-03-30 )
Last Dividend	$0 ( N/A )
Next Dividend	$0 ( N/A )
P/E	-0.140
ATR14	$0 (0.00%)

Insider Trading

Date	Person	Action	Amount	type
2023-07-03	Essetifin Spa	Buy	3 750 000	Common Stock Warrant (right to buy)
2023-07-03	Essetifin Spa	Buy	0	Convertible Promissory Note (right to buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Goldstein Allan L	Buy	480 000	Stock Option (Right to Buy)
2022-05-17	Bove Mauro	Buy	240 000	Stock Option (right to buy)

INSIDER POWER
100.00
Last 98 transactions
Buy: 35 451 124 \| Sell: 5 867 027

RegeneRx Correlation

10 Most Positive Correlations

10 Most Negative Correlations

Did You Know?

Correlation is a statistical measure that describes the relationship between two variables. It ranges from -1 to 1, where -1 indicates a perfect negative correlation (as one variable increases, the other decreases), 1 indicates a perfect positive correlation (as one variable increases, the other increases), and 0 indicates no correlation (there is no relationship between the variables).

Correlation can be used to analyze the relationship between any two variables, not just stocks. It's commonly used in fields such as finance, economics, psychology, and more.

RegeneRx Financials

Annual	2022
Revenue:	$76 761.00
Gross Profit:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2022
Revenue:	$76 761.00
Gross Profit:	$76 761.00 (100.00 %)
EPS:	$-0.0120

FY	2021
Revenue:	$76 761.00
Gross Profit:	$0.00 (0.00 %)
EPS:	$-0.0120

FY	2020
Revenue:	$76 761.00
Gross Profit:	$76 761.00 (100.00 %)
EPS:	$-0.0100

Financial Reports:

No articles found.

RegeneRx

RegeneRx Biopharmaceuticals, Inc., a biopharmaceutical company, focuses on the development of therapeutic peptide, thymosin beta 4, for tissue and organ protection, repair, and regeneration. The company is developing RGN-259, a preservative-free topical eye drop for regeneration of corneal tissues damaged by injury, disease, or other pathology; RGN-352, an injectable formulation to treat cardiovascular diseases, central and peripheral nervous system diseases, and other medical indications; and RGN-137, a topical gel for dermal wounds and reduction of scar tissue. It has strategic partnerships with Lee's Pharmaceutical Group and GtreeBNT Co., Ltd. The company was formerly known as Alpha 1 Biomedicals, Inc. and changed its name to RegeneRx Biopharmaceuticals, Inc. in 2000. RegeneRx Biopharmaceuticals, Inc. was incorporated in 1982 and is based in Rockville, Maryland.